Daily Stock Analysis, AKAO, Achaogen Inc, priceseries

Achaogen Inc. Daily Stock Analysis
Stock Information
Open
1.60
Close
1.42
High
1.63
Low
1.40
Previous Close
1.59
Daily Price Gain
-0.17
YTD High
2.11
YTD High Date
Jan 4, 2019
YTD Low
1.15
YTD Low Date
Jan 3, 2019
YTD Price Change
0.16
YTD Gain
12.70%
52 Week High
15.00
52 Week High Date
May 1, 2018
52 Week Low
1.14
52 Week Low Date
Dec 18, 2018
52 Week Price Change
-9.43
52 Week Gain
-86.91%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 10. 2017
15.46
Jan 25. 2017
17.04
10 Trading Days
10.22%
Link
LONG
Feb 1. 2017
16.83
Mar 14. 2017
25.06
28 Trading Days
48.92%
Link
LONG
Jan 25. 2019
1.38
Feb 1. 2019
1.47
5 Trading Days
6.88%
Link
Company Information
Stock Symbol
AKAO
Exchange
NasdaqGM
Company URL
http://www.achaogen.com
Company Phone
650-800-3636
CEO
Kenneth J. Hillan
Headquarters
California
Business Address
7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001301501
About

Achaogen, Inc. operates as a clinical-stage biopharmaceutical company, which engaegs in discovering, developing, and commercializing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections. It also offers plazomicin for the treatment of serious bacterial infections. The company was by Ian R. Friedland and Nathaniel E. David founded in June 2002 and is headquartered in South San Francisco, CA.

Description

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to to enable patients to receive safe and efficacious doses of plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.